Dechra Pharmaceuticals PLC
LSE:DPH
Dechra Pharmaceuticals PLC
Income from Continuing Operations
Dechra Pharmaceuticals PLC
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Income from Continuing Operations
-£27.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Income from Continuing Operations
£4.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
AstraZeneca PLC
LSE:AZN
|
Income from Continuing Operations
$6.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
23%
|
CAGR 10-Years
12%
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Income from Continuing Operations
-$54.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Indivior PLC
LSE:INDV
|
Income from Continuing Operations
$5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Income from Continuing Operations
$192m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
See Also
What is Dechra Pharmaceuticals PLC's Income from Continuing Operations?
Income from Continuing Operations
-27.9m
GBP
Based on the financial report for Jun 30, 2023, Dechra Pharmaceuticals PLC's Income from Continuing Operations amounts to -27.9m GBP.